Early clinical and biomarker responses after treatment in patients with non-segmental vitiligo.

ABSTRACT: This study was a prospective cohort study in patients with non-segmental vitiligo receiving SoCtreatment. Standard of care treatment involved a potent topical corticosteroid, such as Fluticasonepropionate (FP) cream, used alone or in combination with NB-UVB phototherapy treatment, based ondisease severity per the investigator’s evaluation. For this study, as per institutional guidelines, FP creamwas the first choice for SoC treatment; however, if FP cream was not available, then potent topicalcorticosteroids such as Mometasone furoate (i.e. Elocon, Mometason) or betametasone valerate (i.e.Betnelan, betamethason) were prescribed. Calcineurin inhibitors were used for the face according to theSoC instead of steroids. Study participation did not affect SoC treatment. The study was conducted atthe Netherlands Institute for Pigment Disorders (NIPD), Department of Dermatology, AmsterdamUniversity Medical Center (AMC), University of Amsterdam, The Netherlands

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma, Skin

DISEASE(S): Vitiligo

SUBMITTER: Wouter Ouwerkerk  

LAB HEAD: Rosalie Luiten

PROVIDER: PAD000045 | Pride | 2026-05-19

REPOSITORIES: Pride